[Effectiveness of chemotherapy by the AVM protocol (adriamycin, vincristine and methotrexate) after unsuccessful treatment of patients with non-seminoma using PVB (cisplatin, vinblastine and bleomycin)].
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy*; D013736:Testicular Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D001761:Bleomycin; D014750:Vincristine; D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate
Ocena skuteczności chemioterapii wg programu AVM (adriamycina, winkrystyna, metotreksat) w przypadkach niepowodzeń po leczeniu wg programu PVB (cisplatyna, winblastyna, bleomycyna) u chorych na nienasieniaki.